Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05182723
Other study ID # 20211028-18
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 25, 2021
Est. completion date May 31, 2025

Study information

Verified date January 2022
Source Petrovsky National Research Centre of Surgery
Contact Aleksandr Eremenko, MD
Phone +79037129303
Email aeremenko54@mail.ru
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the effectiveness and the safety of extracorporeal methods for removing mediators of systemic inflammation in patients with multiple organ dysfunction syndrome after heart and aorta surgery.


Description:

After being informed about the study and potential risk, all patients with multiple organ dysfunction syndrome after heart and aorta surgery with indications for extracorporeal removal of inflammatory mediators, giving written informed consent will be included in the study. Patients will be randomized 1:1 ratio to 1. hemoperfusion cartridge for cytokine sorption in combination with an oXiris membrane and 2. oXiris membrane.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date May 31, 2025
Est. primary completion date November 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - multiple organ dysfunction; - SOFA equal to or more than 4; - CRP equal to or more than 100 ng / ml; - increase of IL6 by 5 times or more Exclusion Criteria: - the impossibility to use heparin ( bleeding; heparin-induced thrombocytopenia)

Study Design


Intervention

Procedure:
renal replacement therapy
Extracorporeal Methods for Removing Mediators of Systemic Inflammation

Locations

Country Name City State
Russian Federation Petrovsky Nacional research Centre of Surgery Moscow

Sponsors (1)

Lead Sponsor Collaborator
Petrovsky National Research Centre of Surgery

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Primary CRP ?hange of CRP after 12 hours from baseline value 12 hours from the beginning of the study
Primary CRP ?hange of CRP after 24 hours from baseline value 24 hours from the beginning of the study
Primary CRP comparison of CRP after 12 hours with CRP after 24 hours 24 hours from the beginning of the study
Primary IL6 ?hange of IL6 after 12 hours from baseline value 12 hours from the beginning of the study
Primary IL6 ?hange of IL6 after 24 hours from baseline value 24 hours from the beginning of the study
Primary IL6 comparison of IL6 after 12 hours with IL6 after 24 hours 24 hours from the beginning of the study
Primary SOFA change of SOFA values after 12 hours from baseline value 12 hours from the beginning of the study
Primary SOFA change of SOFA values after 24 hours from baseline value 24 hours from the beginning of the study
Primary SOFA comparison of the SOFA value after 12 hours with the SOFA value after 24 hours 24 hours from the beginning of the study
Secondary extracorporeal therapy duration hospitalisation period, an average of 1 month
Secondary time spent in intensive care unit duration hospitalisation period, an average of 1 month
Secondary inpatient stay time duration through study completion, an average of 2 months
Secondary renal function of RIFLE percentage decrease from initial level through study completion, an average of 2 months
Secondary lethality ratio of the number of deaths to the total number of patients through study completion, an average of 2 months
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)